VeriChip Corporation Announces Sales of VeriTrace System to Two New Jersey Counties

VeriChip Corporation (NASDAQ:CHIP) (�VeriChip�), a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs, announced today that it has sold the VeriTrace� system for disaster relief and emergency management needs to Atlantic and Mercer counties in New Jersey.

Marc Poulshock, Vice President of VeriChip�s Implantable and Emergency Management divisions, said, �These recent orders reflect the continued demand for the VeriTrace system by emergency management personnel and medical examiners throughout the country. Since the federal government continues to support the necessity to be prepared for potential natural catastrophes or acts of terrorism, we will maintain our ongoing discussions with these organizations in the U.S. and internationally.�

The VeriTrace system was created in the aftermath of Hurricane Katrina where it proved helpful in identifying, tracking and accounting for the remains of victims from the hurricane. VeriTrace was used by the Federal Disaster Mortuary Operational Response Team (DMORT) during Hurricane Katrina recovery operations.

VeriTrace is designed to assist state and federal agencies in the management of emergency situations and disaster recovery using implantable RFID technology. The VeriTrace system includes a unique implantable RFID microchip, a VeriTrace Bluetooth� handheld reader, a customized Ricoh 500SE Digital Camera capable of receiving both RFID scanned data and GPS data wirelessly, and a Web-enabled database for gathering and storing information and images captured during emergency response operations. This database ensures the precise collection, storage and inventory of all data and images related to remains and the associated evidentiary items. This also allows the recreation of an accurate and complete reconstruction of a disaster setting, crime scene or similar setting where recreation is necessary.

About VeriChip Corporation

VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed� Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, cleared for medical use in October 2004 by the United States Food and Drug Administration. To complement its healthcare division, VeriChip Corporation established VeriGreen Energy Corporation in March 2009 to focus and invest in the clean and alternative energy sector.

For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.

Statements about VeriChip�s future expectations, including future revenues and earnings from the sale of VeriTrace, and all other statements in this press release other than historical facts are �forward-looking statements� within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip�s actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company�s business is set forth in the Company�s various filings with the Securities and Exchange Commission, including those set forth in the Company�s 10-K filed on February 12, 2009, under the caption �Risk Factors.� The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024